Bavachin protects against diet-induced hepatic steatosis and obesity in mice.

Abstract

Non-alcoholic fatty liver disease (NAFLD) is a major health concern worldwide, and the incidence of metabolic disorders associated with NAFLD is rapidly increasing because of the obesity epidemic. There are currently no approved drugs that prevent or treat NAFLD. Recent evidence shows that bavachin, a flavonoid isolated from the seeds and fruits of Psoralea corylifolia L., increases the transcriptional activity of PPARγ and insulin sensitivity during preadipocyte differentiation, but the effect of bavachin on glucose and lipid metabolism remains unclear. In the current study we investigated the effects of bavachin on obesity-associated NAFLD in vivo and in vitro. In mouse primary hepatocytes and Huh7 cells, treatment with bavachin (20 μM) significantly suppressed PA/OA or high glucose/high insulin-induced increases in the expression of fatty acid synthesis-related genes and the number and size of lipid droplets. Furthermore, bavachin treatment markedly elevated the phosphorylation levels of AKT and GSK-3β, improving the insulin signaling activity in the cells. In HFD-induced obese mice, administration of bavachin (30 mg/kg, i.p. every other day for 8 weeks) efficiently attenuated the increases in body weight, liver weight, blood glucose, and liver and serum triglyceride contents. Moreover, bavachin administration significantly alleviated hepatic inflammation and ameliorated HFD-induced glucose intolerance and insulin resistance. We demonstrated that bavachin protected against HFD-induced obesity by inducing fat thermogenesis and browning subcutaneous white adipose tissue (subWAT). We revealed that bavachin repressed the expression of lipid synthesis genes in the liver of obese mice, while promoting the expression of thermogenesis, browning, and mitochondrial respiration-related genes in subWAT and brown adipose tissue (BAT) in the mice. In conclusion, bavachin attenuates hepatic steatosis and obesity by repressing de novo lipogenesis, inducing fat thermogenesis and browning subWAT, suggesting that bavachin is a potential drug for NAFLD therapy.

• Authors: Xiang Wei, Li Lin, Qian-Qian Yuan, Xiu-Yun Wang, Qing Zhang, Xiao-Min Zhang, Ke-Chao Tang, Man-Yu Guo, Ting-Yu Dong, Wei Han, Da-Ke Huang, Yin-Liang Qi, Mei Zhang, Hua-Bing Zhang
• Journal: Acta pharmacologica Sinica (Acta Pharmacol Sin) Vol. 44 Issue 7 Pg. 1416-1428 (Jul 2023) ISSN: 1745-7254 [Electronic] United States
• PMID: 36721007 (Publication Type: Journal Article)
• Copyright: © 2023. The Author(s), under exclusive licence to Shanghai Institute of Materia Medica, Chinese Academy of Sciences and Chinese Pharmacological Society.

Chemical References

• bavachin
• Glycogen Synthase Kinase 3 beta
• Flavonoids
• Glucose
• Insulin

Topics

• Animals
• Mice
• Non-alcoholic Fatty Liver Disease (metabolism)
• Mice, Obese
• Glycogen Synthase Kinase 3 beta (metabolism)
• Liver (metabolism)
• Obesity (complications, drug therapy, genetics)
• Flavonoids (pharmacology)
• Diet
• Insulin Resistance
• Glucose (metabolism)
• Insulin (metabolism)
• Diet, High-Fat
• Mice, Inbred C57BL